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http://www.biomedcentral.com/1472-6882/14/255RESEARCH ARTICLE Open AccessA pilot controlled trial of a combination of dense
cranial electroacupuncture stimulation and body
acupuncture for post-stroke depression
Sui-Cheung Man1†, Ben H B Hung1†, Roger M K Ng2, Xiao-Chun Yu3, Hobby Cheung4, Mandy P M Fung4,
Leonard S W Li5, Kwok-Pui Leung5, Kei-Pui Leung6, Kevin W Y Tsang6, Eric Ziea7, Vivian T Wong7
and Zhang-Jin Zhang1*Abstract
Background: Our previous studies have demonstrated the treatment benefits of dense cranial electroacupuncture
stimulation (DCEAS), a novel brain stimulation therapy in patients with major depression, postpartum depression
and obsessive-compulsive disorder. The purpose of the present study was to further evaluate the effectiveness of
DCEAS combined with body acupuncture and selective serotonin reuptake inhibitors (SSRIs) in patients with
post-stroke depression (PSD).
Methods: In a single-blind, randomized controlled trial, 43 patients with PSD were randomly assigned to 12 sessions of
DCEAS plus SSRI plus body electroacupuncture (n = 23), or sham (non-invasive cranial electroacupuncture, n-CEA) plus
SSRI plus body electroacupuncture (n = 20) for 3 sessions per week over 4 weeks. Treatment outcomes were measured
using the 17-item Hamilton Depression Rating Scale (HAMD-17), the Clinical Global Impression - Severity scale (CGI-S)
and Barthel Index (BI), a measure used to evaluate movement ability associated with daily self-caring activity.
Results: DCEAS produced a significantly greater reduction of both HAMD-17 and CGI-S as early as week 1 and CGI-S at
endpoint compared to n-CEA, but subjects of n-CEA group exhibited a significantly greater improvement on BI at week
4 than DCEAS. Incidence of adverse events was not different in the two groups.
Conclusions: These results indicate that DCEAS could be effective in reducing stroke patients’ depressive symptoms.
Superficial electrical stimulation in n-CEA group may be beneficial in improving movement disability of stroke patients.
A combination of DCEAS and body acupuncture can be considered a treatment option for neuropsychiatric sequelae
of stroke.
Trial registration: www.clinicaltrials.gov, NCT01174394.
Keywords: Acupuncture, Post-stroke depression, Rehabilitation, Dense cranial electroacupuncture stimulation, DCEAS,
Clinical trialBackground
Mood depression is a common and serious consequence
of stroke. About 30% of stroke patients would develop
post-stroke depression (PSD), either in the early or late
stage after stroke onset [1]. Although PSD is strongly
associated with poor prognosis and increased disability,* Correspondence: zhangzj@hku.hk
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unless otherwise stated.it is often overlooked by clinicians. Only a small portion
of patients are properly diagnosed and receive treatment
[2,3]. Antidepressants, typically represented by selective
serotonin reuptake inhibitors (SSRIs) and heterocyclics,
are the mainstays of treatment for PSD [4,5]. Several
controlled studies have demonstrated that while some
patients significantly improved on depression scores,
others discontinued due to side effects [4,5]. These side
effects may also aggravate patients’ morbidity [1]. On the
other hand, the use of antidepressants might also increased. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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are concurrently taking drugs of other classes [6].
Apart from the general understanding that acupuncture
is effective in chronic pain treatment [7], its efficacy for
post-stroke conditions have also been investigated. A
meta-analysis reported the therapeutic benefits of acu-
puncture on stroke related disability [8]. Another study re-
ported acupuncture as safe and effective in treating PSD
[9]. In a recent systematic review and meta-analysis it has
been suggested that acupuncture might be superior to an-
tidepressants and waitlist controls in improving clinical re-
sponse and reducing depressive symptoms of PSD
patients [9]. However, as a number of these trials lacked
methodological vigour, further appropriately design cli-
nical studies are recommended to verify the conclusions.
Recently we have developed a novel brain stimulation
called dense cranial electroacupuncture stimulation
(DCEAS), in which electrical stimulation is directly deli-
vered on a group of acupoints on the forehead, which are
innervated by the trigeminal sensory pathway [10]. The
benefits of DCEAS have been identified in the treatment
of major depression [11], postpartum depression [12] and
obsessive-compulsive disorder (OCD) [13]. In a recent
clinical trial, it has been demonstrated that electrical
stimulation on scalp acupoints would produce a long-
lasting enhancement of antidepressant efficacy [14]. These
were the reasons to hypothesize that electroacupuncture
could improve clinical outcomes in patients with PSD.
The objective of the present study was to determine
whether DCEAS combined with SSRIs and body acu-
puncture could produce better clinical outcomes in PSD
subjects, as compared to sham (non-invasive cranial
electroacupuncture, n-CEA). To test this hypothesis, this
single-blind, randomized, sham-controlled clinical study
was designed.
Methods
Settings and subjects
This single-blind, randomized, sham-controlled trial was
conducted in Division of Rehabilitation Medicine of Tung
Wah Hospital, Division of Rehabilitation Medicine of
Tung Wah Eastern Hospital, Department of Psychiatry
and Department of Rehabilitation of Kowloon Hospital at
Hong Kong between February 2011 and August 2012. The
study protocol was approved by Institutional Review
Board (IRB) of the University of Hong Kong/Hospital
Authority Hong Kong West Cluster and registered in
www.clinicaltrials.gov (NCT01174394). The reporting of
the trial would adhere to the CONSORT 2010 statement
[15]. The CONSORT checklist and flowchart were in-
cluded as Additional files 1 and 2.
Patients who met all of the following criteria were
eligible for the study: (1) men or women aged 35 to
80 years old; (2) diagnosed as ischemic or haemorrhagicstroke within 6 months, confirmed with cerebral com-
puted topographic scanning or magnetic resonance im-
aging; and (3) developed significant depressive episode,
with score of 16 or greater in the 17-item Hamilton Rating
Scale for Depression (HAMD-17) [16].
Patients who met any of the following criteria were
excluded from the study: (1) presence of severe aphasia,
especially fluent aphasia; (2) presence of severe cogni-
tive dysfunction, as indicated by the Mini-mental State
Examination (MMSE) score < 18 [17]; (3) history of psy-
chiatric illness other than depression; (4) presence of
another chronic disorder, including severe Parkinson’s
disease, cardiac disease, cancers, epilepsy, or chronic al-
coholism; (5) having impaired hepatic or renal function;
or (6) having bleeding tendency.
All participants were able to give voluntary, written
and informed consent on their own before entering the
trial.Randomization and blinding
Subjects of both groups would receive SSRIs and body
electroacupuncture as conventional treatment. They were
randomly assigned to receive DCEAS or n-CEA (sham).
For randomization, simple, complete, non-sequential ran-
dom numbers were generated in advance by a computer
program (SPSS version II) in a block of four, and kept by
the Principal Investigator (PI, ZJZ). After a patient’s eligi-
bility was confirmed, a randomization number which cor-
responded to the group allocation would be provided to
the acupuncturist (BHBH) by PI. Such arrangement would
ensure the clinical assessor (MSCM) and subjects to be
blind to the allocation.Treatment procedures
SSRI treatment regimens
Subjects of both groups received orally administered
SSRIs for 4 weeks in an open manner. For those who were
currently under SSRIs treatment, they would continue
their existing treatment regimens. For those who were not
medicated at the time of trial, fluoxetine (FLX) was given
at an initiate dose of 10 mg/day and escalated to an opti-
mal dose within one week, based on individual patient re-
sponse, and the maximum dose was set at 40 mg/day. In
the week of FLX initiation, acupuncture procedure also
started spontaneously (see below). FLX was selected be-
cause it is one of the most frequently prescribed SSRIs
worldwide [18], and it can enhance motor recovery in
ischaemic stroke patients [19]. Subjects who had poor
compliance with medication schedules (below 80%) would
be removed from the study. Concomitant use of other
psychoactive agents was generally not allowed, but the use
of benzodiazepines for insomnia was permitted as long as
these were taken no more than 14 days cumulatively.
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Acupuncture intervention was conducted for 3 sessions
per week over 4 consecutive weeks while subjects were
being medicated with SSRIs. The 4-week treatment du-
ration was designated because robust effects of acupunc-
ture in stroke patients were generally observed within this
period [9]. Both groups of subjects received body electroa-
cupuncture by electrically stimulating between ipsilateral
Hegu (LI4) and Quchi (LI11) and between ipsilateral
Zusanli (ST36) and Taichong (LR3) on both sides. These
body acupoints were commonly used in the acupunc-
ture for stoke treatment. Meanwhile, subjects assigned to
DCEAS received electrical stimulation on the following 6
pairs of cranial acupoints: Baihui (GV20) and Yintang (EX-
HN3), left Sishencong (EX-HN1) and Toulinqi (GB15),
right Sishencong (EX-HN1) and Toulinqi (GB15), bilateral
Shuaigu (GB8), bilateral Taiyang (EX-HN5), and bilateral
Touwei (ST8). For electrical stimulation on limbic and cra-
nial acupoints, disposable acupuncture needles (0.30 mm in
diameter and 25–40 mm in length) were inserted at a depth
of 10–30 mm obliquely into limbic and cranial acupoints,
on which electrical stimulation with continuous waves with
2 Hz at 9 volts were delivered through an electrical acu-
puncture stimulation instrument (Hwarto, SMY-10A). The
use of the low frequency rather high frequency was adopted
because it could induce biochemical changes in the brain in
more favourable manner for alleviating depressive symp-
toms [20,21]. The intensities of stimulation were adjusted
to a level at which subjects felt most comfortable. The
stimulation lasted 30 min.
For subjects assigned to n-CEA, Streitberger’s non-
invasive acupuncture needles were applied to serve as
sham control at the same cranial acupoints with the
same stimulation modality, except that the needles were
only adhered to the skin instead of insertion [22]. Its va-
lidity and credibility has been well demonstrated [22-24].
Briefly, needles without sharp tips were quickly put onto
the acupoints as used in DCEAS. The needles did not
actually pierce through the skin, though subjects would
feel like being treated. The needles were then affixed on
the skin with adhesive tapes. Since all the cranial acu-
points were beyond subjects’ vision, they could not
visualize the acupuncture procedure. This sham acu-
puncture modality has also been adopted in our previous
studies [11-13], without any problems encountered.Rehabilitation therapy
In view of the fact that a large proportion of stroke pa-
tients had physical rehabilitation treatment, subjects par-
ticipating in the study would be allowed to continue their
designated physical rehabilitation therapy. Whether sub-
jects had had rehabilitation therapy would be included in
statistical analysis as a covariate (see below).Clinical assessment
Subjects’ cognitive function was measured using MMSE
during screening. Those with MMSE score less than 18
were excluded from the study as mentioned in the inclu-
sion criteria. The primary efficacy was measured using the
HAMD-17, CGI-S, and Barthel Index (BI). BI is a concise
index of independence to score movement ability of a pa-
tient in caring himself/herself [25]. Adverse events were
assessed using the Treatment Emergent Symptom Scale
(TESS) [26]. Assessments were conducted at baseline, week
1, 2 and 4. To ensure consistency and reliability of assess-
ments across the study, assessors received a training ses-
sion. A reliability coefficient of ≥ 0.80 was required to be
achieved after the training session on HAMD-17 and BI.
Assessments for a patient were generally completed by the
same assessor.
To check the credibility of the n-CEA and DCEAS proce-
dures, based on the method by Flink et al. [24], each subject
was asked the same question at the end of the last clinical
assessment: “As we informed you that you had an equal
chance of receiving sham or active acupuncture treatment,
which do you think you had received?”.
Data analysis
Previous studies have shown that acupuncture intervention
could produce at least a 4-point reduction in HAMD-17 in
PSD patients [9]. Therefore, a sample size of 40 subjects
(n = 20 per group) should provide an approximately 80%
power at a statistical level of 0.05, with an estimated stan-
dard deviation of 4.0 and an estimated dropout rate of 15%
at the endpoint of treatment.
Efficacy analyses were performed on the intention-to-
treat population, defined as participants who completed
baseline and at least one evaluation after treatment. A lin-
ear mixed-effect model was applied to compare treatment
outcomes (HAMD-17, CGI, and BI) over time between the
two groups. The model was established using time and
group for categorical fixed factors and random intercepts
with scaled identity covariance matrix. Subject’s age, gender,
duration of the illness, baseline HAMD-17 and BI were
treated as covariates. Between-group differences at each
measure time point were further examined using Student
t test. Student t test was also applied to detect between-
group differences in continuous baseline variables. Catego-
rical variables, including categorical baseline variables and
incidence of adverse events were analyzed using Chi-square
(χ2) or Fisher Exact test. Statistical significance was defined
as a two-tailed P< 0.05. The analyses were performed with
SPSS version 16 software (Chicago, IL, USA).
Results
Baseline characteristics of subjects
Of 345 patients screened, 43 eligible subjects were ran-
domly assigned to n-CEA (sham) (n = 20) and DCEAS
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ment, but all subjects completed baseline and at least
one evaluation after treatment. All 43 subjects were
therefore included in data analysis (Figure 1). There
were no significant differences between the two groups
in baseline variables. All subjects had received physical
rehabilitation therapy when they entered the study. A
majority of subjects (86%) were having SSRIs treatment
at study entry and 78% of them were treated with FLX.
All subjects had received rehabilitation therapy with 1–2
sessions when they entered the study. Cognitive function
measured with MMSE was similar in the two groups
(Table 1). The compliance with acupuncture and SSRI
treatment was approximately nearly 95% in the two
groups.
Credibility of n-CEA and DCEAS
For subjects treated with n-CEA, 90% (18/20) of them
perceived to have received DCEAS, while 13.0% (3/23)
subjects in DCEAS group perceived to have received
n-CEA treatment. Using fisher exact test, it yielded no
significant difference in the credibility rating (p = 1.0).
Efficacy
Changes in score from baseline on HAMD-17, CGI-S,
and BI over time are illustrated in Table 2 and Figure 2.
Linear mixed-effects model revealed a significant dif-
ference on the intercept between n-CEA and DCEAS
groups in CGI-S (F = 14.220, df = 1,169, P = 0.0002), and
on the slope in BI (F = 24.101, df = 1,168, P< 0.0001).Figure 1 Enrollment flow. Of 345 patients screened, 43 eligible subjects w
group. For n-CEA (sham), 14 subjects completed; while for DCEAS, 19 compThere was a borderline significance on the slope in
CGI-S (F = 3.716, df = 1,168, P = 0.0556). No significant
differences in HAMD-17 were observed between the two
groups on either slope (F = 0.031, df = 1,168, P = 0.86) or
intercept (F = 3.224, df = 1,169, P = 0.0744). Between-
group comparisons exhibited that DCEAS-treated sub-
jects had a significantly greater reduction in HAMD-17 at
week 1 (P = 0.007) and CGI-S at week 1 (P = 0.001) and
week 4 (P = 0.001). Significantly greater improvement on
BI was observed in subjects receiving n-CEA at week 4
(P< 0.001) compared to DCEAS group.
Medication and rehabilitation profile
There was no significant difference in the average dose
of FLX taken during 4 weeks of treatment between
DCEAS-treated and n-CEA groups (21.2 ± 8.0 mg/day
vs. 21.8 ± 8.1 mg/day, mean ± SD, P = 0.820). The pro-
portion of subjects medicated with benzodiazepines for
insomnia was not significantly different, with 39% (9/23)
for DCEAS group and 55% (11/20) for n-CEA group
(P = 0.366). All subjects continued their rehabilitation
with 1–2 sessions per week.
Safety and tolerability
A total of 12 reported adverse events occurred in at least
5% of subjects in either group are summarized in Table 3.
No significant differences were found between the two
groups in the incidence of any adverse events. None of
the subjects discontinued their treatments due to ad-
verse events.ere randomly assigned to n-CEA (sham) (n = 20) and DCEAS (n = 23)
leted.
Table 1 Baseline characteristics of subjects
Variables n-CEA (n = 20) DCEAS (n = 23) P valueb
Female, n (%) 13 (65.0) 14 (60.9) 0.780
Age (y)a 66.5 ± 11.9 66.7 ± 13.6 0.969
Having previous stroke, n (%) 2 (10.0) 6 (26.1) 0.250
Post-stroke duration (m)a 10.2 ± 14.9 7.7 ± 11.6 0.547
Duration of PSD onset (m)a 4.9 ± 12.0 4.7 ± 10.7 0.953
Having antidepressant treatment at study entry, n (%)c 0.222
Fluoxetine (FLX) 14 (70.0) 15 (65.2)
Other antidepressant agentsd 5 (25.0) 3 (13.0)
Previous acupuncture experience, n (%) 14 (70.0) 13 (56.5) 0.362
Baseline MMSEa 23.5 ± 4.4 24.8 ± 4.8 0.354
Baseline HAMD-17a 28.1 ± 7.0 25.8 ± 5.0 0.225
Baseline CGI-Sa 4.8 ± 0.8 4.9 ± 0.5 0.580
Baseline BIa 37.8 ± 10.7 37.7 ± 11.3 0.975
aContinuous data are expressed as mean ± SD.
bStudent t test and Fisher Exact test were used to detect between-group differences of continuous and categorical data, respectively.
cDuration of antidepressant treatment largely varied from 10 days to 2 years.
dOther antidepressants were sertraline, citalopram, escitalopram, mirtazapine and flupentixol + melitracen.
BI Barthel Index, CGI-S Clinical Global Impression-Severity, DCEAS Dense Cranial Electroacupuncture Stimulation, HAMD-17 17-item Hamilton Rating Scale for
Depression, MMSE Mini-Mental Status Examination, n-CEA Non-invasive Cranial Electroacupuncture, PSD Post-stroke Depression.
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The present study showed that DCEAS treatment pro-
duced a significantly greater reduction on HAMD-17 at
week 1 and CGI-S at week 1 and week 4 compared to
n-CEA controls, although the effects were small. The
incidence of adverse events was not different in the
two groups; there were no subjects who discontinuedTable 2 Changes in score on depression scales from
baseline in PSD subjects
Variables n-CEA DCEAS Slope Intercept
(n = 20) (n = 23) F P F P
HAMD-17 0.031 0.860 3.223 0.074
Week 1 -0.1 ± 1.9 -1.9 ± 2.3**
Week 2 -6.5 ± 1.9 -6.8 ± 2.3
Week 4 -11.2 ± 1.9 -11.6 ± 2.3
CGI-S 3.716 0.056 14.220 <0.001
Week 1 0.1 ± 0.3 -0.3 ± 0.3**
Week 2 -0.7 ± 0.3 -0.8 ± 0.3
Week 4 -1.4 ± 0.3 -1.7 ± 0.3**
BI 24.101 <0.001
Week 1 0.1 ± 1.2 0.0 ± 0.8
Week 2 1.3 ± 1.2 0.7 ± 0.8
Week 4 3.9 ± 1.2 1.8 ± 0.8**
aOverall and between-group P values were obtained from linear mixed-effects
model analysis and student t-test, respectively. **P< 0.01 compared to
n-CEA group.
BI Barthel Index, CGI-S Clinical Global Impression-Severity, DCEAS Dense Cranial
Electroacupuncture Stimulation, HAMD-17 17-item Hamilton Rating Scale for
Depression, n-CEA Non-invasive Cranial Electroacupuncture, PSD Post-stroke
Depression.treatments due to intolerance to needling stimulation.
These results are highly consistent with our recent trials
of DCEAS in major depression [11] and postpartum de-
pression [12], indicating that DCEAS is effective in rapidly
reducing PSD of stroke patients. Our most recent study
has further showed that electrical stimulation on scalp
acupoints even produced a long-lasting enhancement of
antidepressant effects in patients with major depression
[14]. However, we noticed that the magnitude of DCEAS
effects in reducing PSD observed in the present study was
smaller than that that in our previous trials. This may be
largely due to relatively smaller sample size.
It was interesting to observe that subjects of n-CEA
group had better treatment outcomes than DCEAS group
on movement disability associated with daily self-caring
activity. As for n-CEA, though the needle did not pierce
through the skin, similar electrical stimulation was also
applied. The superficial electrical stimulation on the scalp
appeared to be more beneficial in improving limbic par-
alysis. It is known that many forms of non-invasive brain
stimulation, including transcutaneous electrical nerve sti-
mulation (TENS), mainly excite mechanoreceptors and
thick myelinated afferent nerve fibers, such as Aβ and Aδ;
whereas DCEAS is a noxious stimulation that mainly ex-
cites noxious receptors of the scalp [10]. The activation of
mechanoreceptors and thick myelinated afferent nerve
fibers appeared to be more efficacious in alleviating loco-
motor impairment [10]. This could probably explain the
clinical empiricism that physiotherapy and traditional
Chinese medicine (TCM) massage (tui-na) are generally
more effective in rehabilitating limbic paralysis of stroke
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Figure 2 Changes in score from baseline on HAMD-17, CGI-S,
and BI over time.
Table 3 Adverse events occurred in at least 5% of
subjects in either groupa
Event n-CEA (n = 20) DCEAS (n = 23)
Fatigue 8 (40.0) 11 (47.8)
Needling-induced discomfort 6 (30.0) 7 (30.4)
Headache 6 (30.0) 4 (17.4)
Dizziness 1 (5.0) 4 (17.4)
Nausea 2 (10.0) 1 (4.3)
Vomiting 0 2 (8.7)
Depression deterioration 2 (10.0) 3 (13.0)
Movement disorder 3 (15.0) 5 (21.7)
Sweating 1 (5.0) 1 (4.3)
Palpitation 1 (5.0) 5 (21.7)
Insomnia 3 (15.0) 6 (26.1)
Hypersomnia 2 (10.0) 8 (34.8)
aThere were no significant differences in any adverse event between the two
groups, as examined with Fisher Exact test.
DCEAS dense cranial electroacupuncture stimulation, n-CEA non-invasive
cranial electroacupuncture.
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depression and post-stroke disability also connoted that
the greater improvement of DCEAS on PSD was unlikely
due to the improvement of movement ability. This is in
line with a higher prevalence of depressive symptoms of
stroke patients than orthopaedic patients with similar level
of movement disability [17].
There should be a specific neural mechanism respon-
sible for the effects of DCEAS in reducing PSD. Stroke
not only results in the primary ischemic lesion, but also
interrupts central neurotransmitter functions [27], in par-
ticular the brainstem serotonin (5-HT) and noradrenaline
(NA) neuronal systems, which play a pivotal role in modu-
lating mood activity and processing acupuncture signals
[10]. DCEAS was developed mainly based on a neurobio-
logical rationale. It is well documented that the forehead
acupoints innervated by the trigeminal sensory pathway
have intimate connections with the brainstem reticular
formation, in particular the dorsal raphe nucleus (DRN)and the locus coeruleus (LC) [10]. The latter two brain
structures are the major resources of 5-HT and NA neu-
ronal bodies, respectively, sending diffuse projections to
subcortical and cortical areas, including the prefrontal
cortex and the amygdala known to be heavily involved in
the pathogenesis of depression [10]. Neuroimaging studies
have shown that electroacupuncture stimulation is capable
of directly modulating the activity of the emotion proces-
sing-related brain regions [28]. Through the intimate col-
lateral connection from the trigeminal sensory pathway to
the brainstem 5-HT and NA neuronal systems, the need-
ling of the forehead acupoints with subsequent electrical
stimulation could more efficiently elicit afferent acupunc-
ture signals via biophysical and biochemical reactions at
local acupoints and, in turn, modulates central 5-HT and
NA neuronal functions [10]. Our recent study further
showed that active acupuncture results in lateralisation
of functional cerebral response to the contralateral un-
affected hemisphere in patients with unilateral stroke, sug-
gesting that acupuncture could enhance a compensatory
process by redistributing functions to the unaffected
hemisphere [29].
There are several limitations in the present study.
First, electrical stimulation was directly delivered on the
scalp in both n-CEA and DCEAS procedures. This may
elicit a transcutaneous and/or transcranial effect; how-
ever, such effect should be minimal as the stimulation
intensity used in both n-CEA and DCEAS was much
lower than other brain stimulations, such as repetitive
transcranial magnetic stimulation (rTMS), electrocon-
vulsive therapy (ECT) and TENS [30,31]. Therefore, the
greater effects of DCEAS are most likely to be derived
from biophysical and biochemical actions of needling
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milar to most previous studies [9], the determination of
body acupoints used in the present study was basically
based on empirical evidence. Empirical treatment regi-
mens have resulted in a large variation in acupuncture
protocols and difficulties in comparing treatment out-
comes among trials. Finally, although the present study
demonstrated the antidepressant efficacy of acupuncture
therapy, the underlying mechanisms are not yet well de-
lineated. Previous studies have suggested that the anti-
depressant effects of acupuncture may be associated
with the restoration of decreased neuroimaging activity
of brain regions involved in processing emotional signals
[10]. The determination of neuroimaging correlates of
the clinical improvement in depressed patients would
help gain some insights into antidepressant mechanisms
of acupuncture.
Conclusions
These results indicate that DCEAS could be effective in
reducing stroke patients’ depressive symptoms. Superficial
electrical stimulation in n-CEA group may be beneficial in
improving movement disability of stroke patients. A com-
bination of DCEAS and body acupuncture can be consi-
dered a treatment option for neuropsychiatric sequelae of
stroke.
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